Published in Probl Tuberk on January 01, 1986
[Genetic marking of polyresistant mycobacterium tuberculosis strains isolated in the north-west of Russia]. Probl Tuberk (1999) 1.40
Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84
[Virulence of Mycobacteria tuberculosis]. Probl Tuberk (2002) 0.83
[The rate and pattern of drug resistance in Mycobacterium tuberculosis at various sites of the disease]. Probl Tuberk Bolezn Legk (2008) 0.83
[Diagnostic values of polymerase chain reaction test in females with genital tuberculosis]. Probl Tuberk (1998) 0.80
[Combined therapy of pulmonary tuberculosis by using recombinant interleukins]. Probl Tuberk Bolezn Legk (2003) 0.77
[Pulmonary tuberculosis caused by Mycobacterium tuberculosis of different genotypes]. Probl Tuberk Bolezn Legk (2003) 0.77
[Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.76
[Effectiveness of new diagnostic drug Diaskintest in children for tuberculosis diagnostic]. Probl Tuberk Bolezn Legk (2009) 0.76
[The genome polymorphism of the Mycobacterium avium subsp. hominissuis strains]. Mol Gen Mikrobiol Virusol (2014) 0.76
[Influenza vaccination of patients with pulmonary tuberculosis in the tuberculosis dispensary]. Probl Tuberk (1983) 0.75
[Vaccination against influenza in pulmonary tuberculosis patients]. Probl Tuberk (1980) 0.75
[Use of the KEF-1 device for the concentration of Mycobacterium tuberculosis]. Lab Delo (1986) 0.75
[Antihypoxant activity and mechanisms of action of some natural and synthetic compounds]. Eksp Klin Farmakol (2005) 0.75
[Effect of acridine compounds on stopping the development of drug resistance in Mycobacterium tuberculosis (an experimental study)]. Probl Tuberk (1977) 0.75
[Sensitivity and specificity of polymerase chain reaction based test in the diagnosis of peripheral lymph node tuberculosis]. Probl Tuberk (1998) 0.75
[Molecular-genetic characteristics of Mycobacterium tuberculosis strains isolated from patients with tuberculous spondylitis]. Zh Mikrobiol Epidemiol Immunobiol (2014) 0.75
[Levamisole treatment of experimental tuberculosis]. Probl Tuberk (1981) 0.75
[Effectiveness of the combined use of antihypoxic agents and antioxidants in tuberculosis]. Probl Tuberk (1988) 0.75
[Genotypic characteristics of Mycobacterium avium subsp. hominissuis strains]. Genetika (2013) 0.75
[Prevention of experimental traumatic shock by levomepromazine]. Farmakol Toksikol (1972) 0.75
[Clinical significance of virulence of Mycobacterium tuberculosis]. Probl Tuberk (1972) 0.75
[Effectiveness of chlorprothixene in the combined treatment of pulmonary tuberculosis patients]. Probl Tuberk (1986) 0.75
[Peculiarities of newly detected primary tuberculosis in children]. Pediatriia (1969) 0.75
[Electrophysiological characteristics and energy provision of the brain function in traumatic shock]. Patol Fiziol Eksp Ter (1977) 0.75
[Effectiveness of the method of electrophoretic concentration of Mycobacteria]. Probl Tuberk (1986) 0.75
[Evaluation of the severity of tuberculous process in mouse lung]. Probl Tuberk (1993) 0.75
[Effect of plasmapheresis on the course of experimental tuberculosis and the tolerance of chemotherapy by patients with renal tuberculosis]. Probl Tuberk (1992) 0.75
[Energy metabolism in the brain during experimental hemorrhagic shock]. Vopr Med Khim (1990) 0.75
[Method of determining the activity of primary tuberculosis in children]. Probl Tuberk (1971) 0.75
[Design and study of new agents having antitubercular activity: the original compound perchlosone as a potent agent of etiotropic therapy for tuberculosis]. Probl Tuberk (1999) 0.75
[Evaluation of the hepatotoxicity of isoniazid using the bromsulphalein test in animal experiments]. Probl Tuberk (1983) 0.75
[Morphologic characteristics of pathological changes in the lungs in experimental tuberculosis in rats with immunodeficiency, and its correction]. Probl Tuberk (1984) 0.75
[Identification of L-forms of Mycobacterium tuberculosis complex by polymerase chain reaction (PCR)]. Probl Tuberk (2001) 0.75
[Characteristics of Mycobacterium tuberculosis strains circulating in Pskov region]. Zh Mikrobiol Epidemiol Immunobiol (2012) 0.75
[Determining dehydrogenase activity as a method of accelerated indication of the viability of Mycobacterium tuberculosis]. Probl Tuberk (1992) 0.75
[Influence of deoxyribonuclease and ribonuclease on the growth and drug resistance of M. tuberculosis]. Probl Tuberk (1978) 0.75
[Use of isoniazid with nitrofuran and 5-NHQ derivatives in experimental tuberculosis]. Probl Tuberk (1976) 0.75
[Development of an experimental tuberculous process in the presence of immune deficiency and immunostimulation]. Biull Eksp Biol Med (1981) 0.75
[The role of T-cell immunity in tuberculosis resistance in rats]. Probl Tuberk (1983) 0.75
[Basis for intermittent therapy of tuberculosis]. Probl Tuberk (1972) 0.75
[Comparative evaluation of different methods in determining the virulence of Mycobacterium tuberculosis]. Probl Tuberk (1973) 0.75
[Efficacy of immunotropic drugs in experimental tuberculosis]. Probl Tuberk (1985) 0.75
[Prehospital care in traumatic shock]. Vestn Khir Im I I Grek (1995) 0.75
[Influence of proteolytic enzymes on the mycobacteria and Staphylococcus aureus and on their drug resistance]. Probl Tuberk (1977) 0.75
[Plasmid profile of mycobacteria spread on the territory of the Russian Federation]. Probl Tuberk (1998) 0.75
[Some regularities of an immune response in patients with pulmonary tuberculosis and drug-resistant Mycobacterium strains]. Probl Tuberk Bolezn Legk (2008) 0.75
[Molecular genetic characteristics of Mycobacterium tuberculosis isolated from patients operated on for pulmonary tuberculosis]. Probl Tuberk (2002) 0.75
[Combined effect of histones and antibiotics in vitro and in vivo. Antibacterial effect of histone fractions of the calf thymus in combination with streptomycin and tubazid]. Antibiotiki (1972) 0.75
[Fluoroquinolones as antibacterial preparations and their use in the treatment of tuberculosis]. Antibiot Khimioter (2002) 0.75
[Effectiveness and mechanism of action of a new plant complex drug in nonspecific inflammatory processes in the bronchopulmonary system]. Patol Fiziol Eksp Ter (2003) 0.75
[A mathematical model of the epidemic process in tuberculous infection]. Zh Mikrobiol Epidemiol Immunobiol (1997) 0.75
[Cephalosporins as possible methods of etiotropic therapy of tuberculosis]. Probl Tuberk (1993) 0.75
[Immunological parameters and mycobacterial biological properties in infiltrative pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2005) 0.75
[Combined action of histones and anibacterial agents in vitro and in vivo--potentiation of the effect of tubazide]. Dokl Akad Nauk SSSR (1971) 0.75
[Sodium metabisulfite inhibition of the reaction between isoniazid and streptomycin in solution]. Probl Tuberk (1983) 0.75
[Standard model for the study of antishock therapy]. Voen Med Zh (1975) 0.75
[The detection rate and clinical and diagnostic values of L forms of the pathogen in patients with pulmonary or extrapulmonary tuberculosis]. Probl Tuberk (2002) 0.75
[Sensitivity to levofloxacin of various types of non-tuberculosis Mycobacterium]. Antibiot Khimioter (2002) 0.75
[Basic principles of hypoxia control during shock]. Patol Fiziol Eksp Ter (1981) 0.75
[Effect of various methods of immunotherapy on the immunological status of patients with pulmonary tuberculosis]. Probl Tuberk (1984) 0.75
[Concentration of the main antitubercular preparations in the blood serum, urine and renal tissue in renal tuberculosis]. Urol Nefrol (Mosk) (1976) 0.75
[The clinical value of Mycobacterium tuberculosis with different biological properties]. Probl Tuberk (1991) 0.75
[The specific features of bacterial isolation and drug resistance of Mycobacteria in extrapulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2006) 0.75
[Blood bacteriostatic activity in patients with respiratory tuberculosis]. Probl Tuberk (2001) 0.75
[Cytokine production during the development and correction of an immunodeficiency in experimental tuberculosis]. Probl Tuberk (1996) 0.75
[Effect of terrilytin on tissue bacteriostatic activity in the chemotherapy of renal and female genital tuberculosis in an experiment]. Antibiot Med Biotekhnol (1986) 0.75
[Molecular genetic tools for etiologic diagnostics of disseminated lung tuberculosis]. Zh Mikrobiol Epidemiol Immunobiol (2010) 0.75
[Effect of riboxine, levamisole and sodium oxybutyrate on the course of experimental tuberculosis]. Probl Tuberk (1988) 0.75
[Experimental model of combined pathology of tuberculosis-opisthorchiasis]. Patol Fiziol Eksp Ter (1994) 0.75
Effect of gutimin on lactic acid utilization. Bull Exp Biol Med (1974) 0.75
[Bacteriostatic activity of blood and tubazid blood levels after administration of tuberculostatic drugs by various routes (experimental and clinical study)]. Antibiotiki (1972) 0.75
[Effect of terrilytin on the concentration of antitubercular preparations in kidney tissue (experimental research)]. Probl Tuberk (1986) 0.75
[Use of deoxyribonuclease in the treatment of experimental tuberculosis]. Probl Tuberk (1981) 0.75
[Microbiological and molecular genetic characterization of Mycobacterium tuberculosis strains isolated from patients with multiorgan and generalized tuberculosis]. Probl Tuberk Bolezn Legk (2003) 0.75
[Course of experimental shock in tibial fractures]. Patol Fiziol Eksp Ter (1977) 0.75
[Potentiating the specific activity of isoniazid and streptomycin by benzimidazole derivatives]. Probl Tuberk (1987) 0.75
[Characterization of Mycobacterium tuberculosis strains prevalent in North-West of Russia by spoligotyping]. Probl Tuberk (2002) 0.75
[Drug resistance of Mycobacterium tuberculosis in the North-West of Russia]. Probl Tuberk Bolezn Legk (2003) 0.75
[Biological features and problems in detection of extrapulmonary tuberculosis pathogen]. Probl Tuberk (1998) 0.75
[The results of the use of riboxin in the combined treatment of patients with pulmonary tuberculosis]. Probl Tuberk (1989) 0.75
[New approaches to the treatment of mycobacterioses of the lungs]. Probl Tuberk (1991) 0.75
[The combined effect of histones and antibiotics. Treatment of experimental tuberculosis in guinea pigs and white mice with tubazid combined with histones]. Antibiotiki (1974) 0.75
[Chemotherapy of experimental mycobacteriosis]. Probl Tuberk (1988) 0.75
[Levofloxacin susceptibility of Mycobacterium tuberculosis]. Antibiot Khimioter (2005) 0.75
[Anti-asthmatic effect of dimethylene]. Farmakol Toksikol (1968) 0.75
[Accelerated determination of the Mycobacterium tuberculosis drug resistance with a semiliquid culture medium]. Klin Lab Diagn (2003) 0.75
[Use of dimephosphon in pathogenetic therapy of experimental tuberculosis]. Probl Tuberk (1991) 0.75
[Results of inspection of bacteriological laboratories with regard to identification of Mycobacteria]. Probl Tuberk (1985) 0.75
[Experimental and clinical study of preparation Iridol action on the central nevros system]. Eksp Klin Farmakol (2006) 0.75
[Effect of levomepromazine on the epinephrine and norepinephrine content of rat tissues in traumatic shock]. Patol Fiziol Eksp Ter (1972) 0.75
[Effect of DNA-tropic substances used jointly with tuberculostatic preparations on the development of drug resistance in Mycobacterium tuberculosis]. Probl Tuberk (1980) 0.75
[Bacteriological diagnosis of mycobacteriosis: possibilities and prospects]. Probl Tuberk Bolezn Legk (2004) 0.75
[Immunotropic activity of antimicrobial agents used in tuberculosis]. Probl Tuberk (1996) 0.75
[Antihypoxic agents as drugs for pathogenetic therapy of tuberculosis (lecture)]. Probl Tuberk (1994) 0.75
[Intravenous chemo-hormonotherapy in experimental tuberculosis and its effect on some biological properties of the disease-producing agent]. Probl Tuberk (1968) 0.75
[Monitoring of chemotherapy in patients with pulmonary tuberculosis by the blood bacteriostatic activity-determining test]. Probl Tuberk Bolezn Legk (2008) 0.75